This Week’s CGT News: Base Editing Takes Aim at Cholesterol
June 1, 2026
Verve reports phase 1 data for one-time PCSK9 base editing; plus: neuroprotective gene therapy, non-viral DNA delivery, tumour-activated CAR-T, and in vivo CAR-M
3 min read
False
Advertisement
Research News
This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves
May 26, 2026
Merck’s TROP2 ADC delivers a phase III win in endometrial cancer, as new golimumab biosimilars and an oral microbiome therapy move forward
7 min read
This Week’s CGT News: Duchenne Gene Therapy Hits Pivotal Mark
May 25, 2026
REGENXBIO reports phase III AAV data in Duchenne; plus: adenoviral immunotherapy, preconditioning-free CAR-T, in vivo immune programming, and DNA-guided CRISPR
6 min read
This Week’s CGT News: Novo’s Parkinson’s Pivot
May 18, 2026
Novo Nordisk’s Parkinson’s cell therapy finds a new home at Cellular Intelligence, while base editing, prime editing, and large-insertion genome writing push forward
6 min read
This Week’s CGT News: CRISPR Hits Phase 3 Milestone
May 4, 2026
Intellia’s one-time HAE therapy delivers strong results as Cabaletta strikes CAR-T manufacturing deal
6 min read
This Week’s CGT News: New FDA Genome Editing Guidance
April 20, 2026
Our latest roundup highlights tighter FDA expectations for genome editing safety, advances in CRISPR precision and delivery, and continued momentum for off-the-shelf CAR-T
4 min read
Cell and Gene Roundup: CAR T Breaks New Ground
April 15, 2026
A campus-built therapy enters clinical trials as researchers refine gene editing and uncover new ways to control gene expression
5 min read
CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease
April 13, 2026
An investigational Cas12a-edited stem cell treatment sharply boosted HbF and largely eliminated vaso-occlusive crises in an early trial
2 min read
New Iron-Tracking Tool Could Boost Cartilage Regeneration Therapies
April 10, 2026
MIT-led team develops rapid, non-destructive method to predict stem cell quality during manufacturing
1 min read
Gene Therapy for Sickle Cell Could Be Cost-Effective in Uganda
April 9, 2026
New modeling study shows curative treatments may be viable in low-income settings if costs are scaled and societal benefits included
1 min read
